

# clariti<sup>®</sup> 1 day multifocal 3 Add



CooperVision<sup>®</sup>  
Live Brightly.<sup>®</sup>

A convenient daily disposable giving  
you comfort and affordability.\*<sup>1</sup>



If you're noticing changes in your near vision, such as less sharpness when you're reading close up, then look no further than CooperVision<sup>®</sup> clariti<sup>®</sup> 1 day multifocal 3 Add contact lenses. Experience the vision and comfort you deserve at an amazingly affordable price.\*,<sup>†2,3</sup>

clariti<sup>®</sup> 1 day multifocal 3 Add helps patients with presbyopia enjoy the freedom to see like they used to.<sup>4</sup> The all-new lenses incorporate several of CooperVision's advanced technologies to provide all-day comfort and optimal vision, and are easy to put in and take out.<sup>5,6</sup>

## Replacement Schedule



Daily Disposable

## Corrects



Presbyopia

## The features you'll love

- Binocular Progressive System<sup>™</sup> to optimize vision for all levels of presbyopia, even as prescription and vision needs change.<sup>3</sup>
- Optimized Comfort Edge<sup>™</sup> to help provide a high level of comfort.<sup>1</sup>
- WetLoc<sup>®</sup> Technology supports excellent all-day comfort. This naturally wettable silicone hydrogel technology locks in moisture.

**Ask your Eye Care Practitioner if a free trial of  
clariti<sup>®</sup> 1 day multifocal 3 Add would be right for you.**

Please note that free trial does not include eye exam or fitting fees.

\*Pricing is based on manufacturers published MSRP and rebate as of 11/1/23.

<sup>†</sup>Subject rating on a typical day at 2-week visit.

## REFERENCES

1. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti<sup>®</sup> 1 day multifocal 3 add with a rating of 88 out of 100; n=90 habitual MFCL wearers.
2. CVI data on file, 2022. Prospective, crossover, bilateral, subject masked, daily wear, dispensing study (4 clinical sites in U.S.) (n=58 habitual soft MFCL wearers).
3. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti<sup>®</sup> 1 day multifocal 3 add; with ratings from 85 to 89 out of 100; n=90 habitual MFCL wearers.
4. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti<sup>®</sup> 1 day multifocal 3 add; with ratings from 83 to 87 out of 100; n=90 habitual MFCL wearers.
5. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti<sup>®</sup> 1 day multifocal 3 add; n=90 habitual MFCL wearers.
6. CooperVision data on file, 2019. clariti<sup>®</sup> 1 day Wearer Experience Survey conducted online in U.S., n=298: sphere, toric or multifocal; habitual FRP, DD, and new wearers who purchased clariti<sup>®</sup> 1 day; strongly or somewhat agree.

clariti<sup>®</sup>, CooperVision<sup>®</sup>, and WetLoc<sup>®</sup> Technology are registered trademarks of The Cooper Companies, Inc., and its subsidiaries.

©2024 CooperVision 16881 08/24